Quest Diagnostics director acquires shares via DRIP

Quest Diagnostics director Robert B. Carter reported a small acquisition of 11 shares of common stock on July 22, 2026 at $206.804 per share.

Accepted by SEC EDGAR 07/27/2026 - 04:35 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Quest Diagnostics director Robert B. Carter reported a small acquisition of 11 shares of common stock on July 22, 2026 at $206.804 per share. The shares were acquired through a broker-administered dividend reinvestment plan under Rule 16a-6, bringing his direct holdings to 3,864 shares.

Insider Trade Summary

Small Acquisition: 11 shares

Small Acquisition 1 txn

Insider CARTER ROBERT B

Role Director

Type	Security	Shares	Price	Value
Small Acquisition	Common Stock F1	11	$206.804	$2K

Holdings After Transaction: Common Stock — 3,864 shares (Direct)

Footnotes (1)

1. F1. Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4.

Key Figures

Shares acquired: 11 shares Acquisition price: $206.804 per share Holdings after transaction: 3,864 shares

3 metrics

Shares acquired 11 shares Common stock acquired on July 22, 2026 under dividend reinvestment plan

Acquisition price $206.804 per share Price for the 11 Quest Diagnostics common shares acquired

Holdings after transaction 3,864 shares Total direct Quest Diagnostics common stock held by Robert B. Carter after acquisition

Key Terms

dividend reinvestment plan, Rule 16a-6, Form 5, small acquisition

4 terms

dividend reinvestment plan financial

"acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker"

A dividend reinvestment plan lets shareholders automatically use cash dividends to buy more shares of the same company instead of receiving the money. It matters to investors because it turns regular payouts into a steady way to grow ownership and take advantage of compound returns—like having your savings automatically buy additional slices of a pie over time—while often reducing transaction costs and smoothing purchase timing.

Rule 16a-6 regulatory

"eligible for deferred reporting on Form 5 under Rule 16a-6"

Form 5 regulatory

"eligible for deferred reporting on Form 5 under Rule 16a-6"

A Form 5 is an annual report filed with the U.S. securities regulator by company insiders—such as officers, directors and large shareholders—to disclose any equity transactions or holdings that were missed or deferred during the year. Think of it as an end-of-year ledger adjustment that shows final insider ownership and late-reported trades; investors use it to verify insider confidence, detect possible conflicts of interest, and spot unusual patterns in insiders’ buying or selling.

small acquisition regulatory

"transaction code description: Small acquisition under Rule 16a-6"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Quest Diagnostics (DGX) report for Robert B. Carter?

Quest Diagnostics director Robert B. Carter reported acquiring 11 shares of common stock. The transaction occurred on July 22, 2026 through a broker-administered dividend reinvestment plan and was eligible for deferred reporting on Form 5 under Rule 16a-6.

How many Quest Diagnostics (DGX) shares does Robert B. Carter hold after this transaction?

After the reported transaction, Robert B. Carter directly holds 3,864 Quest Diagnostics common shares. This reflects the addition of 11 shares acquired via a dividend reinvestment plan, as disclosed in the SEC insider ownership report.

What price was paid per share in the latest DGX insider acquisition?

The reported acquisition was priced at $206.804 per share. These 11 Quest Diagnostics common shares were obtained automatically through a dividend reinvestment plan rather than an open-market purchase, according to the insider disclosure.

How was the Quest Diagnostics (DGX) insider transaction executed?

The transaction involved shares acquired under a dividend reinvestment plan run by the reporting person’s broker. It qualified for deferred reporting on Form 5 under Rule 16a-6, but the director chose to disclose it early in this insider report.

Is the recent DGX insider transaction part of a Rule 16a-6 small acquisition?

Yes. The filing classifies the 11-share purchase as a small acquisition under Rule 16a-6. Such transactions can be reported later on Form 5, but in this case were voluntarily reported earlier on an insider ownership report.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CARTER ROBERT B

(Last) (First) (Middle)

500 PLAZA DRIVE

(Street)

SECAUCUS NEW JERSEY 07094

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
QUEST DIAGNOSTICS INC [ DGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/22/2026		L	V	11(1)	A	$206.804	3,864	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4.

Remarks:

	Sean D. Mersten, Attorney-in-Fact for Robert B. Carter	07/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)